Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Erica J Wallis Clinical
Pharmacology and Therapeutics, Royal Hallamshire Hospital, Sheffield
S10 2JF
Correspondence
to: L E Ramsay d.colley{at}sheffield.ac.uk
Objective:
To examine the accuracy of a new version of the Sheffield table designed to aid decisions on lipids screening and
detect thresholds for risk of coronary heart disease needed to
implement current guidelines for primary prevention of cardiovascular disease.
Design:
Comparison of decisions made on the basis of
the table with absolute risk of coronary heart disease or
cardiovascular disease calculated by the Framingham risk function. The
decisions related to statin treatment when coronary risk is
30%
over 10 years; aspirin treatment when the risk is
15% over 10 years; and the treatment of mild hypertension when the cardiovascular risk is
20% over 10 years.
Setting:
The table is designed for use in general practice.
Subjects:
Random sample of 1000 people aged 35-64 years from the 1995 Scottish health survey.
Main outcome measures:
Sensitivity, specificity, and
positive and negative predictive values of the table.
Results:
13% of people had a coronary risk of
15%, and 2.2% a risk of
30%, over 10 years. 22% had mild
hypertension (systolic blood pressure 140-159 mm Hg). The table
indicated lipids screening for everyone with a coronary risk of
15%
over 10 years, for 95% of people with a ratio of total cholesterol to
high density lipoprotein cholesterol of
8.0, but for <50% with a
coronary risk of <5% over 10 years. Sensitivity and specificity were
97% and 95% respectively for a coronary risk of
15% over 10 years; 82% and 99% for a coronary risk of
30% over 10 years; and
88% and 90% for a cardiovascular risk of
20% over 10 years in
mild hypertension.
Conclusion:
The table identifies all high risk people for lipids screening, reduces screening of low risk people by more than
half, and ensures that treatments are prescribed appropriately to those
at high risk, while avoiding inappropriate treatment of people at low risk.
© BMJ 2000
Read all Rapid Responses